Atara Biotherapeutics, Inc. — Director's Dealing 2018

Nov 8, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atara Biotherapeutics, Inc. (ATRA)
CIK: 0001604464
Period of Report: 2018-11-07

Reporting Person: MARCUS JOEL S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-11-07	Common Stock	S	10000	$36.35	Disposed	7590	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4000	Indirect
Common Stock	908355	Indirect

Footnotes

F1: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.201 to $36.641. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F2: Consists of shares of common stock held by Alexandria Equities, LLC. Mr. Marcus is the Chairman, CEO and Founder of Alexandria Real Estate Equities, Inc., which is the managing member of Alexandria Equities, LLC, which has full voting and investment power with respect to the shares owned by Alexandria Equities, LLC. As an officer of Alexandria Real Estate Equities, Inc., Mr. Marcus may be deemed to have voting and investment power with respect to the shares owned by Alexandria Equities, LLC. Mr. Marcus disclaims beneficial ownership of the shares held by Alexandria Equities, LLC, except to the extent of his underlying pecuniary interest therein.